Prediction of clinical risks by analysis of preclinical and clinical adverse events

Journal of Biomedical Informatics

Volumn 54, Issue , 2015, Pages 167-173

  Clark, Matthew ^a  

^a ELSEVIER MASSON   (France)

Author keywords

Adverse events; Animal human concordance; Bayesian; Drug risk; Likelihood ratio; Translational medicine

Indexed keywords

CELL DEATH; COMMERCE; DIAGNOSIS; DRUG PRODUCTS; FORECASTING; RISK ASSESSMENT; RISK PERCEPTION; SAFETY ENGINEERING;

ADVERSE EVENTS; BAYESIAN; CLINICAL OBSERVATION; DRUG DEVELOPMENT; HEPATIC FUNCTION; LIKELIHOOD RATIOS; STATISTICAL FRAMEWORK; TRANSLATIONAL MEDICINE;

RISK ANALYSIS;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN;

ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL OBSERVATION; CLINICAL STUDY; DRUG SAFETY; DRUG TREATMENT FAILURE; HEART ARREST; HEART ARRHYTHMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; JAUNDICE; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER NECROSIS; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; RISK; ANIMAL; BAYES THEOREM; DRUG DEVELOPMENT; DRUG SCREENING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; FACTUAL DATABASE; PROCEDURES; RISK ASSESSMENT; TRANSLATIONAL RESEARCH;

ANIMALS; BAYES THEOREM; DATABASES, FACTUAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; HUMANS; RISK ASSESSMENT; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84927927473     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2015.02.008     Document Type: Article

References (26)

1. Guidance for industry nonclinical safety evaluation of drug or biologic combinations. United States Food Drug Adm; 2006, . http://www.fda.gov/OHRMS/DOCKETS/98fr/05d-0004-gdl0002.pdf.
2. Jamieson R.C. Eyelash-dye (Lash-Lure) dermatitis with conjunctivitis. J Am Med Assoc 1933, 20:1560.
3. Wax P.M. Federal food, drug and cosmetic act. Ann Intern Med 1938, 122(1995):456-461. 10.1097/00043764-199607000-00005.
4. Taussig H.B. A study of the German outbreak of phocomelia. J Am Med Assoc 1962, 180:1106-1114. 10.1001/jama.1962.03050260028005.
5. Gad S. Animal models in toxicology 2007, Taylor & Francis Group, Boca Raton.
6. Shanks N., Greek R., Greek J. Are animal models predictive for humans?. Philos Ethics Humanit Med 2009, 4:2. 10.1186/1747-5341-4-2.
7. Goldsmith M.A., Slavik M., Carter S.K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975, 35:1354-1364.
8. Fletcher A.P. Drug safety tests and subsequent clinical experience. J R Soc Med 1978, 71:693-696.
9. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000, 32:56-67. 10.1006/rtph.2000.1399.
10. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007, 334:197. 10.1136/bmj.39048.407928.BE.
11. Bolton C. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Inflammopharmacology 2007, 15:183-187. 10.1007/s10787-007-1607-z.
12. Zbinden G. Predictive value of animal studies in toxicology. Regul Toxicol Pharmacol 1991, 14:167-177. 10.1016/0273-2300(91)90004-F.
13. Heywood R. Clinical toxicity-could it have been predicted? post-marketing experience. In: Lumley CE, Walker S, editors. Animal toxicity studies: their relevance for man. Quay, Lancaster; 1990. p. 57-67.
14. Tabacova S., Kimmel C.A., Wall K., Hansen D., Jackman G.P., Iakovidis D., et al. Atenolol developmental toxicity: animal-to-human comparisons. Birth Defects Res Part A Clin Mol Teratol 2003, 67:181-192.
15. Wall R.J., Shani M. Are animal models as good as we think?. Theriogenology 2008, 69:2-9. 10.1016/j.theriogenology.2007.09.030.
16. Combes R., Grindon C., Cronin M.T.D., Roberts D.W., Garrod J.F. Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation. ATLA Altern Lab Anim 2008, 36:43-63.
17. Pharmapendium. Reed Elsevier Properties SA; 2014. . https://pharmapendium.com.
18. Brown E.G., Wood L., Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999, 20:109-117. 10.2165/00002018-199920020-00002.
19. Mosby's Drug Consult 13th ed. Mosby, St. Louis, MO; 2003.
20. Dukes M.N.G. Meyler's side effects of drugs 1992, Elsevier Science Publishers BV, Amsterdam, Amsterdam. 12th ed.
21. Grimes D.A., Schulz K.F. Refining clinical diagnosis with likelihood ratios. Lancet 2005, 365:1500-1505. 10.1016/S0140-6736(05)66422-7.
22. Chien P.F.W., Khan K.S. Evaluation of a clinical test. II: Assessment of validity. Br J Obstet Gynaecol 2001, 108:568-572. 10.1016/S0306-5456(00)00128-5.
23. Core R. R: a language and environment for statistical computing 2012, R Foundation for Statistical Computing, Vienna, Austria.
24. Aronson J.K. Drug withdrawals because of adverse effects. Side Eff Drugs Annu 2008, 30. 10.1016/S0378-6080(08)00064-0.
25. Morita H., Wu J., Zipes D.P. The QT syndromes: long and short. Lancet 2008, 372:750-763. 10.1016/S0140-6736(08)61307-0.
26. Peters T.S. Do preclinical testing strategies help predict human hepatotoxic potentials?. Toxicol Pathol 2005, 33:146-154. 10.1080/01926230590522121.